Pharmaceuticals
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Trend Stats
1-Month Return
+6.06%
3-Month Return
-0.36%
12-Month Return
+19.62%
Volatility Score
1.6
RSI
58.9
ST Trend
Up
LT Trend
Up
Short-Term Trend
Up
The Short-Term Trend is a metric that gauges an ETF's short-term price trend.
Long-Term Trend
Up
The Long-Term Trend is a metric that gauges an ETF's long-term price trend.
Performance
Pharmaceuticals
S&P 500 Index
Components
| Symbol | Company | Market Cap | 12 mo return Performance over the past 12 months | 3 mo return Performance over the past 3 months | 1 mo return Performance over the past month | Vol Score Our gauge of the ETF's recent volatility | ST Trend A metric that gauges an ETF's short-term price trend | LT Trend A metric that gauges an ETF's long-term price trend |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly & Co | $1T | +42.81% | +13.71% | +20.90% | 3.2 | Up | Up |
| JNJ | Johnson&Johnson | $559B | +55.27% | -1.74% | +7.70% | 1.9 | Neutral | Up |
| ABBV | AbbVie | $394B | +22.83% | -0.07% | +11.84% | 2.5 | Up | Up |
| MRK | Merck | $295B | +52.36% | +2.88% | +7.38% | 2.6 | Neutral | Up |
| AZN | ASTRAZENECA | $282B | +152.78% | -5.91% | +0.32% | 2.1 | Down | Up |
| NVS | Novartis Sp ADR | $279B | +29.56% | -5.63% | +2.12% | 1.7 | Down | Up |
| NVO | Nordisk Sp ADR-B | $182B | -44.34% | +9.77% | -8.42% | 3.1 | Neutral | Down |
| PFE | Pfizer | $146B | +13.15% | -2.56% | +0.08% | 1.8 | Down | Neutral |
| BMY | Bristol-MyersSqu | $113B | +18.68% | -5.88% | +0.57% | 2.5 | Down | Up |
| SNY | SANOFI SP ADR | $105B | -5.36% | +6.44% | +3.28% | 1.8 | Neutral | Down |
| GSK | GSK Sp ADR | $102B | +28.77% | -6.83% | +2.59% | 1.8 | Down | Up |
| MCK | Mckesson | $92B | +11.71% | -16.67% | +6.66% | 2.3 | Down | Down |
| COR | Cencora | $53B | -0.90% | -22.55% | +7.33% | 2.4 | Down | Down |
| TAK | TAKEDA PHARM SP ADR | $50B | +5.47% | -13.00% | -4.50% | 2.0 | Down | Down |
| HLN | Haleon Sp ADR | $39B | -14.60% | -9.91% | +0.11% | 1.8 | Down | Down |
| TEVA | TEVAPHARMIND SP ADR | $39B | +95.85% | +9.37% | -3.58% | 3.2 | Up | Up |
| ZTS | Zoetis-A | $33B | -50.04% | -32.53% | -0.76% | 3.6 | Down | Down |
| VTRS | Viatris | $19B | +86.27% | +14.76% | -4.96% | 2.7 | Up | Up |
| JAZZ | Jazz Pharmaceuti | $15B | +102.82% | +23.62% | +1.51% | 2.9 | Up | Up |
| AXSM | Axsome Therapeut | $12B | +123.49% | +49.33% | +13.00% | 3.3 | Up | Up |
| ELAN | ELANC ANIML HLTH | $12B | +71.33% | +2.34% | +3.59% | 4.6 | Up | Up |
| CORT | Corcept Therapeu | $7.9B | +7.22% | +127.98% | +48.22% | 3.8 | Up | Up |
| OGN | Organon | $3.5B | +34.64% | +105.51% | +0.53% | 0.4 | Up | Up |
| BHC | BAUSCH HEALTH | $1.9B | +1.37% | -3.36% | -10.09% | 4.2 | Down | Down |
| PRGO | Perrigo | $1.6B | -56.03% | +11.48% | -2.04% | 4.5 | Neutral | Down |
| 0 | 0 | 0 | 0 | Bullish | Bullish |